Search for content, post, videos

She is the new CSO at XNK Therapeutics

Anna-Karin Maltais

XNK Therapeutics has announced the appointment of Anna-Karin Maltais as Chief Scientific Officer.

She will be a member of the company’s management team.

“At XNK, Anna-Karin’s experience in research and development will be invaluable as the company continues to grow into new indications,” says Johan Liwing, CEO of XNK Therapeutics. “We are very happy to have her join the team and are confident that she will make an immediate impact within the organization.”

Anna-Karin Maltais

Anna-Karin Maltais, PhD, will be responsible for further developing and implementing XNK Therapeutics’ scientific strategy. She will lead a team responsible for research and innovation with focus on continuing the development of the company’s platform as well as improving the production processes and executing operational research plans.

Dr. Maltais received her PhD. in immunobiology and tumor immunology from Karolinska Institutet in 2006. Since then, she has been leading R&D activities and strategies within several organizations and has also had roles within corporate and business development. Most recently, she comes from Chiesi Farmaceutici S.p.A., a global company that develops and markets therapeutic solutions within a number of different therapeutic areas. At Chiesi, she was Head of CMC, Biotech Research and Product Development, Global Rare Diseases.

Photo of Anna-Karin Maltais: XNK Therapeutics